This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Ophthalmol. 2002;120:1094-1095.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Isotretinoin or Accutane (Hoffman–La Roche Inc, Nutley, NJ; 13-cis-retinoic acid) is a vitamin A analogue that was first licensed in the United States in 1982 for the treatment of cystic acne. Use of isotretinoin during pregnancy is teratogenic and is associated with a constellation of fetal malformations collectively termed retinoic acid embryopathy.¹

Retinoic acid embryopathy is characterized by craniofacial abnormalities in the form of hydrocephalus, microcephaly, a narrow, sloping forehead, hypertelorism, ear deformities, cleft palate, and micrognathia.¹ Systemic anomalies include congenital heart defects and thymic malformation. Reported ophthalmic findings are microphthalmos, optic nerve hypoplasia, and cortical blindness.² We describe a child exposed to isotretinoin during gestation who sought treatment for congenital restrictive ophthalmoplegia and gustatory epiphora (crocodile tears syndrome).

Report of a Case

An 11-week-old boy with numerous malformations came to our unit with a history of poor visual tracking from birth. The child's mother had used isotretinoin (mean daily oral dosage, . . . [Full Text of this Article]

Comment
Corresponding author and reprints: Lawrence Tychsen, MD, Room 2S-89, St Louis Children's Hospital, One Children's Place, St Louis, MO 63110 (e-mail: tychsen@vision.wustl.edu).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?